Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moderate Acid Suppression with Tegoprazan in Gastroesophageal Reflux Disease
ChiCTR2400088259Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of tegoprazan in gastroesophageal reflux disease (GERD) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Healing rate of esophageal mucosal lesions. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
tegoprazan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on ChiCTR2400088259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088259.